Companies›Healthcare›Healthcare›Pharmaceuticals & Biotechnology

BRAWN BIOTECH LTD.

Healthcare › Pharmaceuticals & Biotechnology
₹25.87
at close · 28 Oct 2026
▲ 0.47 (+1.85%)

Latest filings

  1. Routine compliance filing under Regulation 74(5) for Q2 FY27 · Compliance
  2. Brawn Biotech appoints new statutory auditor, re-appoints director · Management Changes
  3. 41st AGM voting results - all 4 resolutions passed with near-unanimous support · Board & Shareholder Meetings
All filings ↓
Ask Nexa about BRAWN BIOTECH LTD.

Snapshot

What the business is, and whether it's a good one at a fair price.

A Pharmaceuticals & Biotechnology company listed on BSE, reporting revenue of ₹17 Cr over the trailing twelve months.

Market Cap
₹8 Cr
P / E (TTM)
8.9×
EV / EBITDA
166.6×
Div Yield
—
Growth
-13.5%▼
Revenue 5y CAGR
PAT — · EBITDA —
Quality
-16.1%·
ROCE (5y median)
ROE -22.8% (5y median) · margin 0.8%
Leverage
0.00·
Debt / Equity · low
Net cash ₹0.28 Cr
Revenue FY21→FY26
0.5×▼
Margin +7.1 pts
₹35 Cr → ₹17 Cr
Moves on a normal day
3.93%·
Median daily move
Last 222 sessions · the yardstick for filing-day moves
Where it sits among 185 Pharmaceuticals peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#15/158
P/B#49/163
ROCE#153/183
ROE#15/166
Debt / Equity#1/166
EBITDA margin#149/165
Revenue growth#114/161
Profit growth#123/158

Scorecard

Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice

Strengths
No borrowings on the balance sheet
lower than 79% of its 166 Pharmaceuticals peers
Negative working-capital cycle — the business is funded by its suppliers
Concerns
Revenue shrinking over 5 years (−14% a year)
Erratic profits — up in only 2 of the last 5 years
Negative returns on capital — −16.1% (5-year median)
#153 of 183 in Pharmaceuticals on the latest reported figures · up from −3.6% in FY21

Charts

How has the market priced it — with filings on the timeline?

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from BRAWN BIOTECH LTD.'s filed financials and exchange disclosures

What does BRAWN BIOTECH LTD. do?

BRAWN BIOTECH LTD. is a Pharmaceuticals & Biotechnology company listed on BSE.

Is BRAWN BIOTECH LTD. profitable?

Yes. Over the trailing twelve months BRAWN BIOTECH LTD. reported a net profit of ₹0.86 Cr on revenue of ₹17 Cr.

Does BRAWN BIOTECH LTD. pay a dividend?

Not in the latest reported year — BRAWN BIOTECH LTD.'s dividend payout for FY26 was nil.

Is BRAWN BIOTECH LTD. debt-free?

Yes. It reported no borrowings on its 31 Mar 2026 balance sheet, and ₹0.28 Cr of cash.

Is BRAWN BIOTECH LTD. expensive compared with its peers?

On trailing P/E, BRAWN BIOTECH LTD. ranks 15 of 158 in Pharmaceuticals — cheaper than 91% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.

How much does the BRAWN BIOTECH LTD. share price move in a day?

On a typical session BRAWN BIOTECH LTD. moves 3.93% — that is the median absolute close-to-close move across its last 222 trading days. MarketPing measures each filing's price reaction against it.

Where can I track BRAWN BIOTECH LTD.'s announcements?

Every NSE and BSE filing by BRAWN BIOTECH LTD. appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.